• Johnson & Johnson disclosed 52-week Phase 3 data for ICOTYDE (icotrokinra), a once-daily oral peptide for moderate-to-severe plaque psoriasis, with results being presented at 2026 American Academy of Dermatology Annual Meeting.
• ICONIC-ADVANCE 1 and 2 showed complete skin clearance (PASI 100) rising from 41% to 49% and 33% to 48% from Week 24 to Week 52.
• Patients switching from placebo to ICOTYDE at Week 16 reached PASI 100 rates by Week 52 of 50% in ADVANCE 1, 43% in ADVANCE 2.
• Safety through one year remained consistent with earlier readouts, with no new safety signals reported through Week 52.
• In ICONIC-LEAD, nearly 60% of adolescents achieved PASI 100 at Week 52, supporting expansion in patients age 12 and older.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603281000PR_NEWS_USPR_____NY20754) on March 28, 2026, and is solely responsible for the information contained therein.